Description
Formalize a process for antibiotic timeouts which meets CMS standards and reduces innapropriate broad spectrum antibiotic use.
A3 - Abx Review and Feedback
PDSA antibiotic timeouts jan. 2020
Core Elements
Action
Appointing a single leader responsible for program outcomes. Experience with successful programs show that a physician leader is effective.
Reporting
Regular reporting information on antibiotic use and resistance to doctors, nurses and relevant staff.
Tracking
Monitoring antibiotic prescribing and resistance patterns.
PDSA Cycles
Progress on PDSA Cycle 1
After ~6 months of antibiotic timeouts, we sat back down with pharmacists to discuss the process and see what opportunities existed for improving our system. We gathered feedback. We found that there were several questions related to the formalized process for timeouts. These were then addressed in the attached word document and communicated back out to the team. To track the progress after these optimizations, we will look at volume of antibiotic timeouts compared to previous as well as our DOT for broad spectrum anti-PSE antibiotics, also attached. Further, we addressed new opportunities related to the the new PNA guidelines where timeouts are encouraged in the de-escalation of broad spectrums w/o growth of MRSA or PSE. We have new metrics were tracking on our use of Amp/Sulbactam, Pip/Tazo, Meropenem and Cefepime in PNA as we are likely overusing these agents. We’re tracking what proportion of our PNA DOT we’re using these agents and shooting for a much lower % than our baseline in Dec. which was ~50%.
Tracking Documents: